Text Size

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

This study has been terminated.
(This trial was terminated due to low recruitment)
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT01467414
First received: October 31, 2011
Last updated: January 3, 2012
Last verified: January 2012
History of Changes

October 31, 2011
January 3, 2012
October 2011
December 2011   (final data collection date for primary outcome measure)
Area under the glucose infusion rate curve during one dosing interval at steady state [ Time Frame: within 0-24 hours after last dosing ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01467414 on ClinicalTrials.gov Archive Site
  • Maximum glucose infusion rate at steady state [ Time Frame: within 0-24 hours after last dosing ] [ Designated as safety issue: No ]
  • Area under the serum insulin degludec concentration-time curve during one dosing interval at steady state [ Time Frame: within 0-24 hours after last dosing ] [ Designated as safety issue: No ]
  • Maximum observed serum insulin degludec concentration at steady state [ Time Frame: within 0-24 hours after last dosing ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes
A Trial Investigating the Pharmacodynamic Properties of NN1250 in Japanese Subjects With Type 2 Diabetes

This trial is conducted in Europe. The aim of this clinical trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) properties of NN1250 in Japanese subjects with type 2 diabetes.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Diabetes
  • Diabetes Mellitus, Type 2
Drug: NN1250
Injected s.c. (under the skin) once daily for 6 days
Experimental: NN1250
Intervention: Drug: NN1250
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
December 2011
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Japanese passport holder
  • Japanese-born parents
  • Type 2 diabetes mellitus (as diagnosed clinically) for at least 12 months
  • Treated with insulin for 3 months prior to screening, alone or in combination with no more than 2 oral antidiabetic drugs (OADs)
  • BMI below or equal to 33.0 kg/m^2
  • HbA1c (glycosylated haemoglobin) below or equal to 10.0%
  • Fasting C-peptide below 1.0 nmol/L

Exclusion Criteria:

  • Use of GLP-1 (Glucagon like peptide-1) receptor agonists (exenatide, liraglutide), thiazolidinediones or DPP-4 inhibitors within 3 months prior to screening
  • Subject who has donated any blood or plasma in the past month or more than 500 mL within 3 months prior to screening
  • Not able or willing to refrain from smoking and use of nicotine gum or transdermal nicotine patches during the inpatient period
  • Supine blood pressure at screening (after resting for 5 min) equal to or higher than 180 mmHg for systolic and/or equal to or higher than 100 mmHg for diastolic
Both
20 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT01467414
NN1250-3763, 2011-001850-27, U1111-1120-7444
No
Novo Nordisk
Novo Nordisk
Not Provided
Study Director: Charlotte Adrian Novo Nordisk
Novo Nordisk
January 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP